Literature DB >> 33447079

Comparison of Intrafractional Motion in Head and Neck Cancer Between Two Immobilization Methods During Stereotactic Ablative Radiation Therapy by CyberKnife.

Chen-Lin Kang1,2,3, Tsair-Fwu Lee1,4,5, Shan-Ho Chan2, Shyh-Chang Liu3, Jui-Chu Wang6, Cheng-Hsiang Tsai1, Kuan-Cho Liao1, Fu-Min Fang1, Liyun Chang7, Chun-Chieh Huang1,8.   

Abstract

PURPOSE: Maintaining immobilization to minimize spine motion is very important during salvage stereotactic ablative radiation therapy (SABR) for recurrent head and neck cancer. This study aimed to compare the intrafractional motion between two immobilization methods. PATIENTS AND METHODS: With a spine tracking system for image guiding, 9094 records from 41 patients receiving SABR by CyberKnife were obtained for retrospective comparison. Twenty-one patients were immobilized with a thermoplastic mask and headrest (Group A), and another 20 patients used a thermoplastic mask and headrest together with a vacuum bag to support the head and neck area (Group B). The intrafractional motion in the X (superior-inferior), Y (right-left), Z (anterior-posterior) axes, 3D (three-dimensional) vector, Roll, Pitch and Yaw in the two groups was compared. The margins of the planning target volume (PTV) to cover 95% intrafractional motion were evaluated.
RESULTS: The translational movements in the X-axis, Y-axis, and 3D vector in Group A were significantly smaller than in Group B. The rotational errors in the Roll and Yaw in Group A were also significantly smaller than those in Group B; conversely, those in the Pitch in Group A were larger. To cover 95% intrafractional motion, margins of 0.96, 1.55, and 1.51 mm in the X, Y and Z axes, respectively were needed in Group A, and 1.06, 2.86, and 1.34 mm, respectively were required in Group B.
CONCLUSION: The immobilization method of thermoplastic mask and head rest with vacuum bag did not provide better immobilization than that without vacuum bag in most axes. The clinical use of 2 mm as a margin of PTV to cover 95% intrafractional motion was adequate in Group A but not in Group B.
© 2020 Kang et al.

Entities:  

Keywords:  CyberKnife; head and neck cancer; immobilization method; intrafractional motion; stereotactic ablative radiation therapy

Year:  2021        PMID: 33447079      PMCID: PMC7802594          DOI: 10.2147/CMAR.S283746

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  20 in total

1.  The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy.

Authors:  M van Herk; P Remeijer; C Rasch; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

2.  Frameless stereotactic radiosurgery for recurrent head and neck carcinoma.

Authors:  George Voynov; Dwight E Heron; Steven Burton; Jennifer Grandis; Annette Quinn; Robert Ferris; Cihat Ozhasoglu; William Vogel; Jonas Johnson
Journal:  Technol Cancer Res Treat       Date:  2006-10

3.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

4.  Inter- and intrafraction patient positioning uncertainties for intracranial radiotherapy: a study of four frameless, thermoplastic mask-based immobilization strategies using daily cone-beam CT.

Authors:  Erik Tryggestad; Matthew Christian; Eric Ford; Carmen Kut; Yi Le; Giuseppe Sanguineti; Danny Y Song; Lawrence Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-15       Impact factor: 7.038

5.  The Continuous Assessment of Cranial Motion in Thermoplastic Masks During CyberKnife Radiosurgery for Trigeminal Neuralgia.

Authors:  Tewfik J Bichay; Alan Mayville
Journal:  Cureus       Date:  2016-05-12

6.  Reirradiation with robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma.

Authors:  Aysen Dizman; Mehtap Coskun-Breuneval; Gonca Altinisik-Inan; Gokce Kaan Olcay; Mehmet Faik Cetindag; Yildiz Guney
Journal:  Asian Pac J Cancer Prev       Date:  2014

7.  Radial displacement of clinical target volume in node negative head and neck cancer.

Authors:  Wan Jeon; Hong-Gyun Wu; Sang Hyuk Song; Jung-In Kim
Journal:  Radiat Oncol J       Date:  2012-03-31

8.  Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.

Authors:  Eric F Lartigau; Emmanuelle Tresch; Juliette Thariat; Pierre Graff; Bernard Coche-Dequeant; Karen Benezery; Luis Schiappacasse; Marian Degardin; Pierre-Yves Bondiau; Didier Peiffert; Jean-Louis Lefebvre; Thomas Lacornerie; Andrew Kramar
Journal:  Radiother Oncol       Date:  2013-11-18       Impact factor: 6.280

9.  Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy.

Authors:  Shane Mesko; He Wang; Samuel Tung; Congjun Wang; Dario Pasalic; Bhavana V Chapman; Amy C Moreno; Jay P Reddy; Adam S Garden; David I Rosenthal; G Brandon Gunn; Steven J Frank; Clifton D Fuller; William Morrison; Jack Phan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-09-30       Impact factor: 7.038

10.  Comparison of set up accuracy among three common immobilisation systems for intensity modulated radiotherapy of nasopharyngeal carcinoma patients.

Authors:  Cheng-Guang Lin; Sen-Kui Xu; Wen-Yan Yao; Yu-Qi Wu; Jian-Lan Fang; Vincent W C Wu
Journal:  J Med Radiat Sci       Date:  2016-09-01
View more
  1 in total

1.  Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells.

Authors:  Zhifeng Wang; Jingmei Liu; Tao Yang; Qinqin Wang; Rong Liang; Jinliang Tang
Journal:  Mol Cell Biochem       Date:  2022-10-11       Impact factor: 3.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.